Biofrontera and Desitin sign marketing and distribution agreement for Ameluz® in Scandinavia
(Thomson Reuters ONE) -
Biofrontera AG /
Biofrontera and Desitin sign marketing and distribution agreement for Ameluz® in
Scandinavia
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen and Hamburg, Germany - Biofrontera Pharma GmbH and Desitin
Arzneimittel GmbH have today closed an agreement according to which Desitin has
obtained exclusive rights to market Biofrontera's new prescription drug
Ameluz(®) in Denmark, Sweden and Norway. Desitin also gets a preferred right of
negotiation for Finland. In December 2011 the European Commission approved
Ameluz(®) for the treatment of actinic keratosis in the entire EU, Norway,
Island and Liechtenstein.
For providing the exclusive marketing rights Biofrontera receives an immediate
significant upfront-payment plus 35% of all net revenues generated by Desitin
with Ameluz(®). In return Biofrontera will deliver the product to Desitin and
take responsibility for the pharmacovigilance structures (drug safety).
All local sales and marketing expenses and the costs required to obtain local
reimbursement will be covered by Desitin. According to the contract Desitin will
launch the product at the latest by October 1, 2012, and has accepted a
commitment to pre-agreed minimum sales.
With this agreement Desitin Arzneimittel GmbH, which in the past was mostly
present on the German market with neurological drugs, has extended its
activities in the Scandinavian market. In these countries, Desitin is active
since 16 years. The company introduced a botulinum toxin A product into the
Scandinavian market 5 years ago, which since then is very successfully
distributed.
Dr. Martin Zentgraf, General Manager of Desitin Arzneimittel GmbH: "We could
convince Biofrontera of our high quality as marketing partner in Scandinavia.
Ameluz(®) is one of the most exciting new medicines in dermatology and we are
lucky to be involved in its distribution."
Comments Prof. Hermann Lübbert, CEO of Biofrontera AG: "Ameluz(®) is to our
knowledge the first prescription drug that was both fully developed and
centrally approved by a small German company. It is now of enormous importance
for the future of both Ameluz® and Biofrontera to make the international
marketing a success, for which the selection of experienced and motivated
distribution partners is most essential. With Desitin we found an excellent
partner for Scandinavia, with a sustained strength in distribution that was
proven with several other products. We are thus proud that we could enthuse
Desitin for the marketing of Ameluz(®)."
Background
Ameluz(®) (developed as BF-200 ALA gel) was centrally approved in the entire
European Economic Area for the treatment of actinic keratosis in December 2011.
The product is applied in the relatively novel photodynamic therapy (PDT). PDT
of actinic keratosis lesions with Ameluz(®) leads to very high efficacy and
excellent cosmetic results, without the side-effects and discomfort of a long-
term treatment. The treatment can be repeated after three months if residual
lesions remain. A direct clinical comparator study proved the strong superiority
of Ameluz(®) compared to its closest competitor.
Actinic keratosis is a superficial skin cancer that is still restricted to the
upper skin layer (the epidermis). These tumours result from UV-light induced
damage accumulating during the entire life time. Thus, they occur very
frequently in sun-exposed skin regions. In about 10-15% of the affected people
the actinic keratosis lesions develop into malignant, potentially fatal squamous
cell carcinomas.
About Biofrontera AG
Biofrontera Pharma GmbH is a wholly-owned subsidiary of Biofrontera AG. The
Biofrontera group aims at attending and treating the skin, recognizing the
aesthetic needs of a person's visual reflection. Biofrontera is listed at the
regulated market of the Düsseldorf stock exchange under the symbol B8F and the
ISIN number DE0006046113.
www.biofrontera.com
This press release contains forward-looking statements based on the currently
held beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the assumptions expressed or implied in this press release to be
faulty. Given these risks, uncertainties and other factors, recipients of this
document are cautioned not to place undue reliance on the forward-looking
statements. Biofrontera AG disclaims any obligation to update these forward-
looking statements to reflect future events or developments.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1582804]
Unternehmensinformation / Kurzprofil:
Datum: 06.02.2012 - 10:16 Uhr
Sprache: Deutsch
News-ID 111132
Anzahl Zeichen: 5712
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera and Desitin sign marketing and distribution agreement for Ameluz® in Scandinavia"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
